Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...

The triumph of Ozempic, Wegovy, and related drugs, including Lilly’s Zepbound, has set off a push toward the next frontier: a ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...

Novo Nordisk A/S (NYSE:NVO) is the manufacturer and distributor of pharma products, though the company is mainly known for ...

Which European healthcare stocks are most attractive right now? Seeking Alpha analysts offer their picks. Read more here.

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...